Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection27
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients25
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective16
The making of the one pill—Developing single tablet regimens for HIV and for HCV15
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting14
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation13
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants13
Commentary: John C. Martin (1951–2021)12
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts12
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir10
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study10
Tenofovir alafenamide fumarate9
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity9
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway9
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report8
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis6
A favipiravir-induced angioedema and urticaria in a COVID-19 patient6
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study6
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud6
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir6
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database5
The transformation of HIV therapy: One pill once a day5
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical s5
0.042374134063721